Incyte Corporation: all 314 studies

Page 1 of 4. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic TherapyNot yet recruitingNCT07862998Phase 2
• A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on HemodialysisNot yet recruitingNCT07854249Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentNot yet recruitingNCT07853040Phase 1
• A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and ChemotherapyNot yet recruitingNCT07823322Phase 2
• Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1Not yet recruitingNCT07797283Phase 3
• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaRecruitingNCT07623200Phase 3
• A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentRecruitingNCT07559474Phase 1
• A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseRecruitingNCT07559396Phase 1
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaRecruitingNCT07522073Phase 3
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsRecruitingNCT07448155Phase 1
• Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerRecruitingNCT07284849Phase 3
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07214779Phase 3
• Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07213973Phase 2
• A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 1
• A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)RecruitingNCT07124078Phase 2
• Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)RecruitingNCT07115004Phase 3
• Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersRecruitingNCT07104565Phase 2
• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionRecruitingNCT07023627Phase 2
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07008118Phase 1
• An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)AvailableNCT06910137
• Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingNCT06855498Phase 3
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoRecruitingNCT06804811Phase 3
• An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisRecruitingNCT06627335
• A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingNCT06615050Phase 3
• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseRecruitingNCT06585774Phase 3
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoRecruitingNCT06548360Phase 3
• Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabRecruitingNCT06465433Phase 2
• Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationRecruitingNCT06259669
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationRecruitingNCT06179160Phase 1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
• Observational Study for Patients at Risk for Chronic Graft-Versus-Host DiseaseRecruitingNCT05919511
• A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT05836324Phase 1
• Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)RecruitingNCT05776069Phase 1/2
• Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseAvailableNCT05561985
• To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaRecruitingNCT05090891Phase 2
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
• A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male ParticipantsCompletedNCT06309394Phase 1Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06263478Phase 3Results posted
• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisCompletedNCT06238817Phase 3Results posted
• Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic DermatitisCompletedNCT06144424Phase 2Results posted
• Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous UrticariaTerminatedNCT06077773Phase 2Results posted
• A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationTerminatedNCT06039384Phase 1Results posted
• A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/2Results posted
• Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedNCT05936567Phase 2Results posted
• Topical Ruxolitinib Evaluation in Chronic Hand EczemaCompletedNCT05906628Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05764161Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05755438Phase 3Results posted
• A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoCompletedNCT05750823Phase 2Results posted
• The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.TerminatedNCT05696392Phase 4Results posted
• Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaCompletedNCT05635838Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen SclerosusCompletedNCT05593445Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen PlanusCompletedNCT05593432Phase 2Results posted
• Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing CholangitisCompletedNCT05525520Phase 2Results posted
• Study of Ruxolitinib Cream in Adolescents With Atopic DermatitisCompletedNCT05456529Phase 3Results posted
• Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05287113Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 AlterationsTerminatedNCT05267106Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationCompletedNCT05253807Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With VitiligoCompletedNCT05247489Phase 2Results posted
• Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsActive, not recruitingNCT05222555Phase 1/2Results posted
• Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis InvolvementCompletedNCT05127421Phase 2Results posted
• Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaTerminatedNCT05073458Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo NodularisCompletedNCT05061693Phase 2Results posted
• The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.TerminatedNCT04949191Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)CompletedNCT04921969Phase 3Results posted
• A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)CompletedNCT04896385Phase 2Results posted
• The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic DermatitisCompletedNCT04839380Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With VitiligoCompletedNCT04818346Phase 2Results posted
• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)TerminatedNCT04809467Phase 1/2Results posted
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.Active, not recruitingNCT04680052Phase 3Results posted
• To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2Results posted
• To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 2Results posted
• Study of INCB086550 in Select Solid TumorsTerminatedNCT04629339Phase 2Results posted
• An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedNCT04586244Phase 2Results posted
• To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaTerminatedNCT04582539Phase 1/2Results posted
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)TerminatedNCT04551066Phase 3Results posted
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)TerminatedNCT04551053Phase 3Results posted
• Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With VitiligoCompletedNCT04530344Phase 3Results posted
• Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic PruritusCompletedNCT04510090Phase 1Results posted
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT04476043Phase 2Results posted
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).CompletedNCT04472429Phase 3Results posted
• INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersCompletedNCT04455841Phase 1/2Results posted
• Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedNCT04434937Phase 2Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced MalignanciesCompletedNCT04370704Phase 1/2Results posted
• Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Phase 3Results posted
• A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedNCT04071366Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)CompletedNCT04057573Phase 3Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)CompletedNCT04052425Phase 3Results posted
• Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)TerminatedNCT04003623Phase 2Results posted
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted
• Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedNCT03978637Phase 1/2Results posted
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaTerminatedNCT03837509Phase 1/2Results posted
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)TerminatedNCT03822117Phase 2Results posted
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745651Phase 3Results posted
• Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745638Phase 3Results posted
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedNCT03721965Phase 1/2Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaTerminatedNCT03656536Phase 3Results posted

← Incyte Corporation overview and focus areas